Adicet bio to participate in guggenheim 2022 oncology conference

Menlo park, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a biotechnology company discovering and developing allogeneic gamma delta car t cell therapies for cancer and other diseases, today announced that chen schor, president and chief executive officer, will participate in a fireside chat at the guggenheim 2022 oncology conference taking place virtually on february 9-11, 2022. details of the event are as follows: date: wednesday, february 9, 2022 time: 11:30 am et a live
ACET Ratings Summary
ACET Quant Ranking